Enanta (ENTA) Pharmaceuticals announced it has commenced an underwritten public offering for $50M of shares of its common stock. All of the shares are being offered by Enanta. J.P. Morgan, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Promising Phase 2b Trial Results for Enanta Pharmaceuticals’ Zelicapavir Boost Buy Rating and $20 Price Target
- Enanta Pharmaceuticals Announces Positive Phase 2b Results
- Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results
- Enanta reports ‘positive’ results from Phase 2b study of zelicapavir
- Enanta announces passing of CFO Paul Mellet Jr.